Plasma microRNA‐based signatures to predict 3‐year postoperative recurrence risk for stage II and III gastric cancer

Abstract

Our aim was to identify plasma microRNA (miRNA)-based signatures to predict 3-year postoperative recurrence risk for patients with stage II and III gastric cancer (GC), so as to provide insights for individualized adjuvant therapy. Plasma miRNA expression was investigated in three phases, involving 407 patients recruited from three centers. ABI miRNA microarray and TaqMan Low Density Array were adopted in the discovery phase to identify potential miRNAs. Quantitative reverse-transcriptase polymerase chain reaction was used to assess the expression of selected miRNAs. Logistic regression models were constructed in the training set (n = 170) and validated in the validation set (n = 169). Receiver operating characteristic analyses, survival analyses and subgroup analyses were further used to assess the accuracy of the models. We identified a 7 miRNA classifier and 7miR + pathological factors index that provided high predictive accuracy of GC recurrence (area under the curve = 0.725 and 0.841 in the training set; and 0.627 and 0.771 in the validation set). High-risk patients defined by the signatures had significantly shorter disease-free survival and overall survival than low-risk patients. The 7 miRNA classifier is an independent prognostic factor, and could add predictive value to traditional prognostic factors. Subgroup analyses revealed the satisfactory performance persisted regardless of stage, and the two models both displayed high accuracy in stage IIA patients. In conclusion, identified microRNA signature may potentially provide some additional benefit for prediction of disease recurrence in patients with stage II and III GC.

Prognostic value of miR-21 in gliomas: comprehensive study based on meta-analysis and TCGA dataset validation

“…Alterations in the expression levels of specific miRNAs can be easily and stably detected in tumor tissues [17][18][19][20] , plasma and serum 36,37 and cerebrospinal fluid (CSF) 38,39 . Therefore, miRNAs are potential tumor biomarkers [40][41][42][43] .…”

Pathological tumor infiltrative pattern and sites of initial recurrence in stage II/III gastric cancer: Propensity score matching analysis of a multi‐institutional dataset

“…Accurate prediction of recurrence sites is extremely important in postoperative follow‐up because early detection of recurrences will be possible by conducting appropriate surveillance . By detecting recurrent lesions early, the first‐line treatment for recurrences can be initiated early.…”

Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility

“…The authors proposed the ratio of miR-106a/let-7a as a marker to differentiate GC from healthy controls (AUC=0.879) 97. A classifier based on a seven miRNA panel (let-7e, miR-125b, miR-126, miR-148a, miR-21, miR-26a and miR-222) coupled with a bioptic pathological index predicted the 3-year recurrence risk in patients with stage II–III GC (training cohort: AUC=0.841, and validation cohort: AUC=0.711), being a putative predictive biomarker in assessing the necessity of adjuvant chemotherapy 98. The accuracy of a plasma-derived five lncRNA panel (TINCR, CCAT2, AOC4P, BANCR and LINC00857) was analysed for GC diagnosis and was found to be superior to carcinoembryonic antigen (CEA) in discriminating GC from healthy controls (AUC=0.91).…”